

Contents

- x Editors' Message
- xi Reviewers
- xii Continuing Medical Education Information

Ham-Wasserman Lecture

- 1 Therapeutic development and current uses of BCL-2 inhibition**
ANDREW W. ROBERTS

A Map for the Changing Landscape of CLL

- 10 Approaches for relapsed CLL after chemotherapy-free frontline regimens**
LINDSEY E. ROEKER AND ANTHONY R. MATO
- 18 EVIDENCE-BASED MINIREVIEW**
Treatment of relapsed chronic lymphocytic leukemia after venetoclax
MEGHAN C. THOMPSON AND ANTHONY R. MATO
- 24 Chemotherapy-free frontline therapy for CLL: is it worth it?**
JOANNA M. RHODES AND JACQUELINE C. BARRIENTOS
- 33 Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy**
CAROL MORENO

Acute Myeloid Leukemia—So Many Treatment Options; How Do You Decide?

- 41 Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?**
EVAN C. CHEN AND JACQUELINE S. GARCIA
- 51 How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia**
ALISON R. WALKER
- 57 Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop**
EUNICE S. WANG AND JEFFREY BARON

Advances in the Laboratory Assessment of Hemostatic and Thrombotic Disorders

- 67 "TEG talk": expanding clinical roles for thromboelastography and rotational thromboelastometry**
RITA SELBY
- 76 Improving interpretation of genetic testing for hereditary hemorrhagic, thrombotic, and platelet disorders**
MICHELE P. LAMBERT
- 82 EVIDENCE-BASED MINIREVIEW**
Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura
ANG LI AND JOHANNA A. KREMER HOVINGA

Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time?

- 85 Can we use epigenetics to prime chemoresistant lymphomas?**

JENNIFER E. AMENGUAL

- 95 Harnessing lymphoma epigenetics to improve therapies***

HAOPENG YANG AND MICHAEL R. GREEN

- 101 Novel targets in aggressive lymphoma**

KAMI MADDOCKS

Beyond the Marrow: Major Nonhematologic Complications of Inherited Bone Marrow Failure Syndromes

- 107 Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes**

CARMEM BONFIM

- 115 Extrahematopoietic manifestations of the short telomere syndromes**

KRISTEN E. SCHRATZ

Caring for Patients with Acute Leukemia in Community Hospitals: Who, What, and When to Refer?

- 123 Optimizing management of acute leukemia in community centers and when to refer**

ANAND P. JILLELLA, JORGE E. CORTES, AND VAMSI K. KOTA

- 129 Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings**

ANNA B. HALPERN AND ROLAND B. WALTER

- 135 Updates in infection risk and management in acute leukemia**

C. LOGAN, D. KOURA, AND R. TAPLITZ

Challenging Situations for Patients with Aggressive Lymphomas

- 140 Approaches to aggressive B-cell lymphomas in less fit patients**

NANCY L. BARTLETT

- 148 Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas**

OREOFE O. ODEJIDE

- 154 Strategies for aggressive T-cell lymphoma: divide and conquer**

LAUREN C. PINTER-BROWN

Chronic Transfusion Support: Challenging Cases

- 160 Challenges in chronic transfusion for patients with thalassemia**

ASHUTOSH LAL

- 167 Outpatient transfusions for myelodysplastic syndromes**

ERICA M. WOOD AND ZOE K. McQUILTEN

- 175 Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life**

JENNIFER WEBB

Diagnostic and Prognostic Models in VTE Management: Ready for Prime Time?

- 184 Can pregnancy-adapted algorithms avoid diagnostic imaging for pulmonary embolism?**

WEE-SHIAN CHAN

- 190 When I treat a patient with acute pulmonary embolism at home**

FREDERIKUS A. KLOK AND MENNO V. HUISMAN

- 195 EVIDENCE-BASED MINIREVIEW**

Advanced therapies and extracorporeal membrane oxygenation for the management of high-risk pulmonary embolism

RADHIKA GANGARAJU AND FREDERIKUS A. KLOK

- 201 Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?**

FIONNUALA NÍ ÁINLE AND BARRY KEVANE

Genetic Testing for Heritable Hematologic Disorders 101

- 213 Informed consent for genetic testing in hematology**

JONATHAN M. MARRON

- 219 Identifying potential germline variants from sequencing hematopoietic malignancies**

IRA L. KRAFT AND LUCY A. GODLEY

Handling Challenging Questions in the Management of CML

- 228 First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?**

VIVIAN G. OEHLER

- 237 How to manage CML patients with comorbidities**

JORGE CORTES

- 243 Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?**

DELPHINE REA

Immunotherapy in Multiple Myeloma

- 248 Sequencing multiple myeloma therapies with and after antibody therapies**

NIELS W. C. J. VAN DE DONK

- 259 EVIDENCE-BASED MINIREVIEW**

Should all newly diagnosed MM patients receive CD38 antibody-based treatment?

CHARLOTTE L. B. M. KORST AND NIELS W. C. J. VAN DE DONK

- 264 Bispecifics, trispecifics, and other novel immune treatments in myeloma**

GUIDO LANCMAN, JOSHUA RICHTER, AND AJAI CHARI

- 272 Future of CAR T cells in multiple myeloma**

KITSADA WUDHIKARN, SHAM MAILANKODY, AND ERIC L. SMITH

Improving Symptom Control for Children with Hematological Malignancies

- 280 Improving symptom control and reducing toxicities for pediatric patients with hematological malignancies**

LILLIAN SUNG, TAMARA P. MILLER, AND ROBERT PHILLIPS

Indolent Lymphomas: Answers to Smoldering Questions

- 287 How do I sequence therapy for follicular lymphoma?**

GILLES SALLES

- 295 How do we sequence therapy for marginal zone lymphomas?**

ALESSANDRO BROCCOLI AND PIER LUIGI ZINZANI

- 306 Transformed lymphoma: what should I do now?**

SONALI SMITH

Infection Risk, Immunization Recommendations, and Antimicrobial Prophylaxis When Treating Nonmalignant Hematologic Disorders

- 312 Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs**

ELISSA R. ENGEL AND JOLAN E. WALTER

319 Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases
LUIS MALPICA AND STEPHAN MOLL

328 Preventing infections in children and adults with asplenia
GRACE M. LEE

Managing Toxicities of Targeted Therapies in CLL

336 Managing toxicities of Bruton tyrosine kinase inhibitors
ANDREW LIPSKY AND NICOLE LAMANNA

346 Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors
ASHLEY HANLON AND DANIELLE M. BRANDER

357 Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia
KIRSTEN FISCHER, OTHMAN AL-SAWAF, AND MICHAEL HALLEK

Monoclonal Gammopathies of Determined Significance

363 Management of AL amyloidosis in 2020
GIOVANNI PALLADINI, PAOLO MILANI, AND GIAMPAOLO MERLINI

372 Management of Waldenström macroglobulinemia in 2020
JORGE J. CASTILLO AND STEVEN P. TREON

380 Monoclonal gammopathies of clinical significance
ANGELA DISPENZIERI

More Anxiety-Provoking Hematology Consults

389 A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact
ARI ZIMRAN, ROSA RUCHLEMER, AND SHOSHANA REVEL-VILK

395 Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease
KENNETH McCLAIN

400 Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP
MICHAEL LINENBERGER AND KLEBER Y. FERTRIN

Myelodysplastic Syndromes: What We Have and What We Want

411 Existing agents, novel agents, or transplantation for high-risk MDS
BART L. SCOTT

418 Patient stratification in myelodysplastic syndromes: how a puzzle may become a map
ANNE SOPHIE KUBASCH AND UWE PLATZBECKER

426 Therapy for lower-risk MDS
HETTY E. CARRAWAY AND CANER SAYGIN

Myeloproliferative Disorders: Too Many Cells, Too Few Therapies

434 Applied genomics in MPN presentation
ALISON R. MOLITERNO AND HANNAH KAIZER

440 Genomics of MPN progression
ANAND A. PATEL AND OLATOYOSI ODENIKE

450 Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes

MRINAL M. PATNAIK AND TERRA L. LASHO

460 EVIDENCE-BASED MINIREVIEW

Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review

MRINAL M. PATNAIK AND TERRA LASHO

Out of Balance: Anemias Due to Disordered Iron Homeostasis

465 Inherited microcytic anemias

MARIA DOMENICA CAPPELLINI, ROBERTA RUSSO, IMMACOLATA ANDOLFO, AND ACHILLE IOLASCON

471 Global look at nutritional and functional iron deficiency in infancy

MICHAEL B. ZIMMERMANN

478 Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?

KLEBER YOTSUMOTO FERTRIN

Pediatric Hematological Malignancies: CARs for Kids

487 Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma

EMILY M. HSIEH AND RAYNE H. ROUCE

494 CAR T cells for other pediatric non-B-cell hematologic malignancies

ADAM J. LAMBLE AND REBECCA GARDNER

501 CAR T cells vs allogeneic HSCT for poor-risk ALL

CAROLINE DIORIO AND SHANNON L. MAUDE

508 EVIDENCE-BASED MINIREVIEW

What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell acute lymphoblastic leukemia?

AIMEE C. TALLEUR AND SHANNON L. MAUDE

Platelet Transfusions for Hematology/Oncology Patients

512 Does ABO and RhD matching matter for platelet transfusion?

NANCY M. DUNBAR

518 How well do platelets prevent bleeding?

DARRELL J. TRIULZI

523 EVIDENCE-BASED MINIREVIEW

The use of premedications for platelet transfusions in pediatric patients

MEGHAN McCORMICK AND DARRELL TRIULZI

527 Platelet transfusion refractoriness: How do I diagnose and manage?

CLAUDIA S. COHN

Selected Hemostasis and Thrombosis Topics in Women

533 Management of heavy menstrual bleeding on anticoagulation

BETHANY SAMUELSON BANNOW

538 EVIDENCE-BASED MINIREVIEW

Abnormal uterine bleeding in users of rivaroxaban and apixaban

AMANDA E. JACOBSON-KELLY AND BETHANY T. SAMUELSON BANNOW

542 Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management

CLAIRE McLINTOCK

547 Women and bleeding disorders: diagnostic challenges

PAULA D. JAMES

The Brain and Pain in Sickle Cell Disease

553 Neuropathic pain in sickle cell disease: measurement and management

ALEXANDER GLAROS AND AMANDA M. BRANDOW

562 Optimizing the management of chronic pain in sickle cell disease

IFEYINWA OSUNKWO, HAZEL F. O'CONNOR, AND ELNA SAAH

The Emerging Role of Targeted Therapies and Cell Therapy in Transplant

570 Next-generation cell therapies: the emerging role of CAR-NK cells

RAFET BASAR, MAY DAHER, AND KATAYOUN REZVANI

579 Practical aspects of building a new immunotherapy program: the future of cell therapy

JESÚS G. BERDEJA

Understanding How to Manipulate the Immune System in Immunotherapy for Lymphoma

585 Fundamentals of immunology for understanding immunotherapy for lymphoma

STEPHEN M. ANSELL

590 Immunotherapy with cells*

ELISE A. CHONG AND DAVID L. PORTER

598 Immunotherapy with drugs

YUN CHOI AND CATHERINE S. DIEFENBACH

Updates on the Role of Nonanticoagulant Interventions in Venous Thromboembolism

606 Role of venous stenting for venous thromboembolism

KAREN BREEN

612 Thrombolytic therapy in acute venous thromboembolism

THITA CHIASAKUL AND KENNETH A. BAUER

619 Inferior vena cava filters: a framework for evidence-based use

AMAR H. KELKAR AND ANITA RAJASEKHAR

629 EVIDENCE-BASED MINIREVIEW

Do prophylactic inferior vena cava filters in trauma patients reduce the risk of mortality or pulmonary embolism?

AMAR H. KELKAR AND ANITA RAJASEKHAR

What Hematologists Need to Know About Giving and Stopping Aspirin

634 Does aspirin prevent venous thromboembolism?

ROBERT DIEP AND DAVID GARCIA

642 Combining antiplatelet and anticoagulant therapy in cardiovascular disease

GEOFFREY D. BARNES

Yin and Yang of Autoimmunity and Immunodeficiencies in Hematology

649 Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency

EMMA C. MORRIS

661 How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation

ROSHINI S. ABRAHAM

673 Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)

MARKUS G. SEIDEL

Erratum

680 Sanz GF. In MDS, is higher risk higher reward? *Hematology Am Soc Hematol Educ Program*. 2019;2019: 381-390.

*Articles Not Eligible for Continuing Medical Education Credit

95 Harnessing lymphoma epigenetics to improve therapies

HAOPENG YANG AND MICHAEL R. GREEN

590 Immunotherapy with cells

ELISE A. CHONG AND DAVID L. PORTER